Agah Ramtin

CMO Agah Ramtin buys 10,000 shares of RNXT at $1.00; fourth buy in 18 days amid -33.8% 52-week decline and $-2.9M net loss.

Agah Ramtin, Chief Medical Officer of RenovoRx, purchased 10,000 shares at $1.00 on 2026-01-21, bringing his holdings to 798,460 shares. This is his fourth open-market purchase within an 18-day window (2025-12-05 through 2026-01-21), a pattern of sequential accumulation at RNXT. The stock is trading at $1.02, down 33.8% from its 52-week high of $1.54 and off 13.6% over the past 90 days despite a +12.1% bounce in the last 30 days. Critically, RenovoRx reported only $266,000 in latest quarterly revenue against a $-2.9M net loss, with negative full-year earnings and a $37.4M market cap—a micro-cap biotech in financial distress. While Ramtin's cross-ticker track record shows an 83.33% 90-day win rate on buys (avg +40.8% return), his five same-ticker purchases at RNXT show mixed near-term results (three measurable 30-day outcomes: +21.2%, -13.0%, +11.9%), with no 90-day outcomes yet available to assess timing. The repeated, discrete purchases over less than three weeks warrant investor attention to whether they reflect conviction in a distressed asset or something else.

CMO Ramtin bought 9,795 shares of RNXT at $0.86; stock down 22.1% over 90 days while company posts $-2.9M net loss.

Agah Ramtin, Chief Medical Officer, purchased 9,795 shares of RenovoRx at $0.86 on 2025-12-31, increasing his holdings to 788,460 shares (+1.3% vs prior). This transaction occurs in the context of RenovoRx's weak fundamentals: the company reported $-2.9M net income in its most recent period and remains unprofitable over its full fiscal year, with minimal revenue of $266.0K. The stock has declined 22.1% over the prior 90 days and is currently 38.3% below its 52-week high of $1.54. While Ramtin's cross-ticker track record shows strong results (11 prior buys averaging +40.8% 90-day returns with 83.33% win rate), his same-ticker history at RNXT shows mixed outcomes: of five measurable prior trades at this ticker, only one achieved a 90-day result (none were well-timed by the 90-day mark). This latest purchase follows three buys within the prior 10 days (2025-12-30, 2025-12-16, 2025-12-05), suggesting sustained accumulation despite ongoing operational losses and negative price momentum.

CMO Agah Ramtin buys 205 shares of RNXT at $0.83; stock down 45.4% from 52-week high, company posting $-2.9M net loss.

Agah Ramtin, Chief Medical Officer, purchased 205 shares at $0.83 on 2025-12-30, adding modestly to his 778.7K-share position. This marks his fifth open-market purchase of RNXT in approximately 40 days (prior buys on 2025-12-31, 2025-12-16, 2025-12-05, 2025-11-24, and 2025-11-21), suggesting sustained accumulation despite deteriorating price action. The stock has declined 45.4% from its 52-week high and 7.1% over the past 30 days, while the company reported $266.0K in quarterly revenue against a $-2.9M net loss, indicating ongoing unprofitability. His cross-ticker buying record shows a 83.33% 90-day win rate with an average 90-day return of +40.8%; however, at RNXT specifically, the timing of his earlier buys remains unmeasurable at the 90-day horizon, offering no evidence of accuracy in this particular equity.

CMO Agah Ramtin buys 12,000 shares of RenovoRx at $0.85, accumulating 778.5K shares amid unprofitable fundamentals and recent repeat purchases.

Agah Ramtin, RenovoRx's Chief Medical Officer, purchased 12,000 shares at $0.85 on 2025-12-16, adding to recent buying activity at this ticker with purchases also made on 2025-12-05, 2025-11-24, and 2025-11-21. His cross-ticker track record shows 9 prior open-market buys with an average 90-day return of +40.8% and an 83.33% win rate; however, at RNXT specifically, timing outcomes are mixed—his 2025-04-15 buy returned +55.6% at 90 days, but his 2025-06-05 buy returned -10.7% at 90 days. The current stock price of $0.87 is -43.5% from its 52-week high of $1.54 and +8.2% over 30 days, but the company reported revenue of $266.0K in the latest quarter with net income of -$2.9M and a market cap of $31.9M, indicating continued losses and a micro-cap profile. The repeated purchases within a compressed timeframe coupled with unresolved fundamental weakness warrant monitoring of whether these accumulations reflect insider conviction or reflect volatility-driven execution in a distressed valuation environment.

CMO Agah Ramtin buys 10,000 RNXT shares at $0.96 amid -39.0% 52-week decline; stock down 19.0% in 90 days.

Agah Ramtin, Chief Medical Officer of RenovoRx, purchased 10,000 shares at $0.96 on 2025-12-05, expanding his holdings to 766.5K shares. This acquisition occurs while the stock trades at $0.94, down -39.0% from the 52-week high of $1.54 and down -19.0% over the prior 90 days. Ramtin's five prior trades at RNXT show mixed timing: two were measurable with -2.9% and -10.7% 90-day returns, while earlier buys in April produced +23.3% and +32.5% 30-day returns and +55.6% and +67.5% 90-day returns. His cross-ticker track record across 8 other open-market buys shows an 83.33% 90-day win rate with an average 90-day return of +40.8%, but that success does not guarantee performance at this ticker. The company's fundamentals remain challenged: most recent quarter revenue of $266.0K with net income of $-2.9M and unprofitability over the full fiscal year. The timing and scale of this buy relative to the recent sell-off warrants attention to whether it signals management confidence or reflects other considerations.

CMO Agah Ramtin purchases 22,000 shares at $0.80 in 2 transactions; stock down 48.7% from 52-week high, 33.0% in 30 days.

Agah Ramtin, Chief Medical Officer, executed 2 separate purchases totaling 22,000 shares for $17,600.00 at $0.80 per share on 2025-11-21 and 2025-11-24, increasing his holdings by 3.0% to 756,460 shares. The timing follows significant recent price deterioration: the stock is down 48.7% from its 52-week high and down 33.0% over the prior 30 days, now trading at $0.79. Ramtin's prior trades at RNXT show a pattern of well-timed buys, with 4 of 5 prior purchases showing positive 90-day returns (ranging from +23.3% to +67.5%), and his cross-ticker track record shows a 90d win rate of 83.33% with average 90d returns of +40.8%. The company context is challenged: latest quarter revenue was $266.0K with a net loss of $-2.9M, and the company was unprofitable over its most recent full fiscal year. The purchases occur against a backdrop of both demonstrated insider buy timing success at this ticker and deteriorating financial fundamentals.

CMO buys 21,000 RNXT shares at $1.40; +29.2% in 30 days; 5 prior RNXT buys, all positive 30d returns.

Agah Ramtin, Chief Medical Officer of RenovoRx, purchased 21,000 shares at $1.40 on 2025-06-05, bringing holdings to 734.5K shares. This marks his sixth purchase of RNXT in as many weeks—all five prior buys at this ticker (2025-04-08 through 2025-04-15) returned between +23.3% and +34.3% within 30 days, with the stock currently up +29.2% from this week's transaction price. His cross-ticker track record shows 100% win rate on 90-day buy outcomes with an average 90d return of +15.2%. However, the company remains unprofitable (net income: $-2.4M in full year, $197.0K revenue in latest quarter) and carries a $50.1M market cap, so the price movement reflects trading momentum rather than fundamental strength. The concentrated buying pattern over five weeks combined with consistent short-term gains warrants close observation of whether this reflects genuine conviction in pipeline catalysts or exposure to potential momentum reversal.

CMO Agah Ramtin bought 15,000 RNXT shares at $0.90; cluster of 4 insiders buying in 14 days amid 90-day decline of -32.0%

Agah Ramtin, Chief Medical Officer, purchased 15,000 shares at $0.90 on 2025-04-15, adding to holdings of 1.11M shares. This represents his third open-market purchase at RNXT within a 7-day window (prior buys on 2025-04-11 and 2025-04-09), with 3 other insiders also buying within the past 14 days—a notable cluster pattern. The purchases occur against a 90-day backdrop of -32.0% stock decline and 52-week range of $0.77–$1.54, with current price $1.02 trading 33.8% below the 52-week high. The company remains unprofitable (full-year net income: $-2.5M; market cap $37.3M). His cross-ticker track record shows 100% 90-day win rate with average 90d return +15.2%, but prior RNXT trades (completed 2024-01-26 or earlier) are not yet full benchmarks; the recent cluster of rapid purchases lacks measurable outcomes. The pattern warrants observation for signals about management's view of current valuation or strategic positioning.

CMO Agah Ramtin buys 20,000 shares of RNXT at $0.80; cluster buy pattern detected with 3 other insiders in 14 days.

Agah Ramtin, Chief Medical Officer, purchased 20,000 shares at $0.80 on 2025-04-11, expanding his holdings to 1,098,460 shares. This transaction is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated or concurrent conviction among the leadership. Ramtin has demonstrated a strong cross-ticker track record with 3 prior buys averaging +34.3% return over 30 days and +15.2% over 90 days at a 100.00% win rate, indicating a history of sound timing on open-market purchases. However, the stock is down -45.4% from its 52-week high of $1.54 and the company is unprofitable (net income of $-2,471,000.00), presenting material headwinds despite the insider buying activity.

CMO Agah Ramtin bought 30,000 shares of RNXT at $0.81 (2025-04-09); cluster of 3 other insiders buying within 14 days; stock down 48.7% from 52-week high.

Agah Ramtin, Chief Medical Officer, purchased 30,000 shares at $0.81, increasing his holdings to 1,078,460 shares. This buy occurred within a cluster pattern: 3 other insiders also bought within the past 14 days. His cross-ticker track record shows 2 prior buys with an average 90-day return of +15.2% and a 100% win rate, though at RNXT specifically, his prior buy on 2024-01-26 achieved a 90-day return of +15.2%. However, the stock is currently down 48.7% from its 52-week high and has declined 40.6% over the past 90 days, indicating significant recent pressure despite the insider's historical success with timing. The company is unprofitable, with net income of $-2,471,000 over the full fiscal year, which contextualizes the risk profile of this accumulation.